Mapping out strategies to overcome challenges in clinical research
In the backdrop of geopolitical disruptions impacting supply chains in many industries, the healthcare and pharma sectors are facing several…
All articles by Irena Maragkou
Irena Maragkou
Irena Maragkou is a Healthcare Researcher for Clinical Trials Arena and Pharmaceutical Technology based in London, UK. Irena previously worked in consulting at Deloitte’s Strategy, M&A and Analytics Department, focusing on projects in the Pharmaceutical and Healthcare Sector. She holds an MSci degree in Neuroscience from UCL.
-
-
Obesity trial surge puts the focus back on decentralisation
The rise of GLP-1 receptor agonists (GLP-1RAs) has ignited a surge in the obesity market in recent years, transforming treatment…
-
Digital tools offer opportunity to lower clinical trial costs
In a clinical trial, there is a bigger burden of implementing digital tools on the contract research organisation (CRO) than…
-
Gamification could help improve patient retention and engagement in clinical trials
Gamification could be a potential solution to addressing patient engagement and compliance in clinical trials, said Christer Nilsson, CEO of…
-
The course to forging long-term manufacturing partnerships for gene therapies
The current adeno-associated virus (AAV) vector manufacturing landscape in 2024 is a “buyer’s market” with companies competing for clinical trial…
-
Charting the road to operational success in clinical trials
At the upcoming 12th Annual Outsourcing in Clinical Trials & Clinical Trial Supply Nordics meeting, experts from the pharmaceutical, biotechnology…
-
Era of ADCs: Pharma companies innovate to stand out in a buzzing market
Antibody drug conjugates (ADCs) have taken over the cancer clinical research and dealmaking landscape, with new partnerships and agreements being…
-
Will anti-homosexuality bills in sub-Saharan Africa impede HIV research?
As sub-Saharan African countries introduce more anti-homosexuality bills, there are concerns they could create a barrier to the LGBTQI+ community…
-
Flexibility of alternative trial designs crucial for cell and gene therapy research
The traditional randomised controlled trial (RCT) model has been used for decades in drug development. Although it is considered the…
-
GLP1-RAs beyond obesity and diabetes: Is the sky the limit?
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have taken the type 2 diabetes and obesity market by storm. Outside of the pharmaceutical…